Abstract:Lay summary: Obesity is frequently accompanied by a fatty liver. However, some individuals with high abdominal fat levels nevertheless have low levels of liver fat. Reasons for such discordant phenotypes are unclear. In this paper, we report that among asymptomatic individuals with high levels of visceral fat, low concentrations of IGFBP-2 in the circulation were associated with significantly higher hepatic fat content compared to those with high IGFBP-2 levels. We conclude that quantification of plasma IGFBP-2 concentrations may be useful to identify the early risk for liver fat accumulation in apparently healthy individuals without cardiovascular symptoms. Aim/hypothesis: Although excess visceral adiposity (VAT) is generally associated with increased liver fat (LF), recent evidence has revealed heterogeneity in LF content among adults with visceral obesity, potentially contributing to specific differences in cardiometabolic outcomes. Reasons for such discordant VAT-LF phenotypes are largely unknown. The present study aimed at assessing whether circulating levels of insulin growth-factor binding protein-2 (IGFBP-2) could be a useful biomarker in the identification of heterogenous and discordant VAT-LF phenotypes. Methods: A sample of 308 middle-aged Caucasian apparently healthy men and women without cardiovascular symptoms were studied for the present cross-sectional analyses. Fasting plasma glucose and lipid levels were assessed and an oral glucose tolerance test was performed. Hepatic fat fraction (HFF) was measured using magnetic resonance spectroscopy whereas VAT was assessed by magnetic resonance imaging. Plasma IGFBP-2 levels were quantified by ELISA. Participants were then classified on the basis of median VAT (81 mL) and IGFBP-2 levels (233 ng/mL). Results: Individuals with high levels of VAT were characterized by higher waist circumference, lower insulin sensitivity, as well as by higher plasma triglyceride and lower HDL-cholesterol levels. Plasma IGFBP-2 levels were inversely correlated with HFF (r = -0.39, p < 0.0001). Among men and women with high levels of VAT, those with low levels of IGFBP-2 had significantly higher HFF (7.5 ± 0.7%), compared to participants with high IGFBP-2 concentrations (3.2 ± 0.5%, p < 0.0001). Conclusion: In the presence of excess VAT, high IGFBP-2 concentrations are associated with low levels of LF. Although additional studies will be necessary to establish causality and further clarify the clinical implications of these observations, these findings are concordant with a novel function of IGFBP-2 in modulating susceptibility to non-alcoholic fatty liver disease (NAFLD) in the presence of visceral obesity.

Circulating Igfbp-2 Levels Are Inversely Associated With The Incidence Of Nonalcoholic Fatty Liver Disease: A Cohort Study

[The Association Between Body Mass Index and Non-Alcoholic Fatty Liver Disease].

Insulin-like Growth Factor Binding Protein 1 Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease

IGFBP-2 As a Biomarker in NAFLD Improves Hepatic Steatosis: an Integrated Bioinformatics and Experimental Study

Serum Fetuin B Level Increased in Subjects of Nonalcoholic Fatty Liver Disease: a Case-Control Study.

Serum Apob Levels Independently Predict the Development of Non-Alcoholic Fatty Liver Disease: A 7-Year Prospective Study

Serum betatrophin level increased in subjects with nonalcoholic fatty liver disease

Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis

IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway

Serum Proteomic Analysis Revealed Diagnostic Value of Hemoglobin for Nonalcoholic Fatty Liver Disease

Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.

Association Between Serum Growth Hormone Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study.

Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: A large-scale prospective cohort study

Serum Adipocyte Fatty Acid‐binding Protein Levels: an Indicator of Non‐alcoholic Fatty Liver Disease in Chinese Individuals

Fetuin-B Links Nonalcoholic Fatty Liver Disease to Type 2 Diabetes Via Inducing Insulin Resistance: Association and Path Analyses.

Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD

Serum interleukin-38 levels correlated with insulin resistance, liver injury and lipids in non-alcoholic fatty liver disease

High Serum Level of Fibroblast Growth Factor 21 is an Independent Predictor of Non-Alcoholic Fatty Liver Disease: A 3-Year Prospective Study in China

Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity

Plasma Osteoprotegerin Levels Are Inversely Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Case–control Study in China

Clinical Significance of Serum IGF-I, IGF-II and IGFBP-3 in Liver Cirrhosis